Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | AOCs: future outlooks in other disease areas

Arthur Levin • 6 Apr 2022
AAN 2022
Duchenne Muscular Dystrophy Neuromuscular Disorders Antibodies

Arthur Levin, PhD, Avidity Biosciences, La Jolla, CA, briefly discusses the future of antibody-oligonucleotide conjugates (AOCs) for the treatment of neuromuscular disorders, commenting on the possibility of targeting several different cell surface receptors and using a variety of monoclonal antibodies (mAbs) to deliver therapeutic agents and treat a wide range of diseases. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.

Disclosures

Dr Levin is an employee of Avidity Biosciences, a Board member at Stoke Therapeutics, and a SAB member at Atalanta Therapeutics.

More from Arthur Levin

4:11
AOCs in neuromuscular disorders: Duchenne muscular dystrophy
Arthur Levin • 6 Apr 2022
1:53
AOC for the treatment of Duchenne muscular dystrophy in exon 44 skippers
Arthur Levin • 6 Apr 2022
4:27
AOC programs in development for DMD and myotonic dystrophy
Arthur Levin • 6 Apr 2022

Related Videos

3:01
Results of pridopidine use in the Phase II HEALEY-ALS platform trial
Michael Hayden • 16 Apr 2024
1:12
Functional electrical stimulation: beyond stroke
Rosalyn Grabarz • 12 Oct 2023
0:52
Latest regarding SMA biomarkers for disease monitoring and treatment response
Robert Muni-Lofra • 2 Jul 2023
1:32
The changing therapeutic landscape of SMA
Robert Muni-Lofra • 2 Jul 2023
The content of VJNeurology is intended for healthcare professionals